Publications by authors named "KEREKES G"

Background: High-dose chemotherapy followed by autologous hematopoietic stem cell support is recommended in the treatment of eligible multiple myeloma (MM) patients. The aim of this study was to compare the efficacy and safety of steady-state versus chemotherapy-based stem cell mobilization in our Hungarian patient population.

Methods: The subjects were 210 MM patients who underwent stem cell mobilization procedure between 2018 and 2022.

View Article and Find Full Text PDF

The co-occurrence of myasthenia gravis (MG) and paroxysmal nocturnal hemoglobinuria (PNH) is rare; only one case has been published so far. We report a 63-year-old Caucasian female patient who was diagnosed with MG at the age of 43. Thymoma was also detected, and so it was surgically resected, which resulted in reasonable disease control for nearly 20 years.

View Article and Find Full Text PDF
Article Synopsis
  • - Cardiovascular issues are common in patients with rheumatoid arthritis (RA) and ankylosing spondylitis (AS), and natural autoantibodies (nAAbs) play a role in inflammation and atherosclerosis linked to these conditions.
  • - A study involving 53 patients treated with anti-TNF therapies over a year found improvements in vascular function and stabilization of vascular thickness, while also noting changes in nAAb levels.
  • - The research suggests that nAAbs may independently affect autoimmunity and vascular health in biologic-treated patients, highlighting a complex relationship between arthritis, inflammation, and cardiovascular risks.
View Article and Find Full Text PDF

The interaction between laser beams and backscattering object surfaces lies at the fundamental working principle of any Terrestrial Laser Scanning (TLS) system. Optical properties of surfaces such as concrete, metals, wood, etc., which are commonly encountered in structural health monitoring of buildings and structures, constitute an important category of systematic and random TLS errors.

View Article and Find Full Text PDF
Article Synopsis
  • - Researchers studied serum levels of HE4 as a biomarker for pulmonary inflammation in COVID-19 patients, identifying a correlation between HE4 levels and disease severity as well as patient outcomes.
  • - The study analyzed 99 COVID-19 patients (divided into critically ill, severe, and mild) alongside 25 control patients with bacterial sepsis, measuring HE4 levels and examining their relationship with clinical markers.
  • - Results showed significantly higher HE4 levels in critically ill patients, which correlated with age, SOFA scores, and severity, indicating HE4 can serve as an independent prognostic indicator of both disease severity and mortality in COVID-19, with a key predictive threshold identified.
View Article and Find Full Text PDF
Article Synopsis
  • The study investigates how 12 months of tofacitinib treatment affects the Renin-Angiotensin-Aldosterone system (RAAS) in rheumatoid arthritis patients, particularly focusing on angiotensin converting enzyme (ACE) and ACE2 levels.
  • Twenty-six RA patients completed the study, revealing that tofacitinib treatment significantly increased serum ACE levels and the ACE/ACE2 ratio after one year, while ACE2 activity only showed a temporary increase at six months.
  • The results suggest a link between baseline inflammation, disease duration, and specific biomarkers (like rheumatoid factor) with changes in the ACE/ACE2 ratio during the treatment period.
View Article and Find Full Text PDF
Article Synopsis
  • The study aimed to assess the effects of tofacitinib therapy on angiogenic factors and vascular health in patients with rheumatoid arthritis (RA).
  • Over one year, 26 RA patients treated with tofacitinib showed significant reductions in certain inflammatory cytokines and growth factors, indicating a potential decrease in synovial and aortic inflammation.
  • The findings suggest that after one year of treatment, certain biomarkers like NT-proBNP and CathK may indicate vascular health, linking them to blood vessel function in RA patients.
View Article and Find Full Text PDF

The investigation of arterial stiffening is a promising approach to estimating cardiovascular risk. Despite the widespread use of different methods, the dynamic nature of measured and calculated stiffness parameters is marginally investigated. We aimed to determine the stability of large artery elasticity parameters assessed via commonly used, ultrasound-based and oscillometric methods in relation to peripheral resistance modulation.

View Article and Find Full Text PDF
Article Synopsis
  • This study investigates how tofacitinib, a JAK inhibitor, impacts metabolic changes associated with rheumatoid arthritis (RA) over one year, focusing on arginine and methionine levels and their connection to inflammation and cardiovascular health.
  • Thirty RA patients were monitored for inflammatory markers, vascular function, and various amino acid levels before and after treatment, revealing significant decreases in inflammatory markers but no major changes in vascular function.
  • After 12 months, higher doses of tofacitinib increased certain amino acids like L-arginine and methionine, with mixed correlations noted between these amino acids and inflammation, but no overall improvement in vascular function metrics was observed.
View Article and Find Full Text PDF
Article Synopsis
  • JAK inhibitor tofacitinib, used for treating rheumatoid arthritis (RA), shows a complex impact on lipids and metabolic markers related to cardiovascular health over a one-year period.
  • In a study involving 30 RA patients, several lipid and adipokine levels were monitored, revealing significant changes in certain markers like TC, HDL, LDL, and TSP-1, while others remained stable.
  • The study found correlations between metabolic indicators, clinical markers, and vascular functions, suggesting that tofacitinib therapy influences CV risk factors and highlights the need for comprehensive evaluations in RA patients.
View Article and Find Full Text PDF

Introduction: Angiotensin-converting enzyme (ACE) and ACE2 have been implicated in the regulation of vascular physiology. Elevated synovial and decreased or normal ACE or ACE2 levels have been found in rheumatoid arthritis (RA). Very little is known about the effects of tumor necrosis factor α (TNF-α) inhibition on ACE or ACE2 homeostasis.

View Article and Find Full Text PDF

Objective: To develop recommendations for cardiovascular risk (CVR) management in gout, vasculitis, systemic sclerosis (SSc), myositis, mixed connective tissue disease (MCTD), Sjögren's syndrome (SS), systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS).

Methods: Following European League against Rheumatism (EULAR) standardised procedures, a multidisciplinary task force formulated recommendations for CVR prediction and management based on systematic literature reviews and expert opinion.

Results: Four overarching principles emphasising the need of regular screening and management of modifiable CVR factors and patient education were endorsed.

View Article and Find Full Text PDF

Objectives: Angiotensin-converting enzyme 2 (ACE2) represents the primary receptor for SARS-CoV-2 to enter endothelial cells. Here we investigated circulating ACE2 activity to predict the severity and mortality of COVID-19.

Methods: Serum ACE2 activity was measured in COVID-19 (110 critically ill and 66 severely ill subjects at hospital admission and 106 follow-up samples) and in 32 non-COVID-19 severe sepsis patients.

View Article and Find Full Text PDF

Background: Cardiovascular (CV) morbidity, mortality, and metabolic syndrome are associated with rheumatoid arthritis (RA) and ankylosing spondylitis (AS). Here, lipids and other metabolic markers in relation to vascular function and clinical markers were evaluated in RA and AS patients undergoing one-year anti-TNF therapy.

Patients And Methods: Fifty-three patients including 36 RA patients treated with either etanercept (ETN) or certolizumab pegol (CZP) and 17 AS patients treated with ETN were included in a 12-month follow-up study.

View Article and Find Full Text PDF

Cardiovascular (CV) disease and osteoporosis (OP) have been associated with rheumatoid arthritis (RA) and ankylosing spondylitis (AS). Bone and vascular biomarkers and parameters along with the effect of 1-year anti-TNF therapy on these markers were assessed in order to determine correlations between vascular pathophysiology and bone metabolism in RA and AS. Thirty-six patients treated with etanercept or certolizumab pegol and 17 AS patients treated with ETN were included in a 12-month follow-up study.

View Article and Find Full Text PDF

Objective: Rheumatoid arthritis (RA) and ankylosing spondylitis (AS) have been associated with cardiovascular disease. The treatment of arthritis by tumor necrosis factor-α (TNF-α) inhibitors may decrease the serum concentrations of vascular biomarkers. We determined circulating levels of oxidized low-density lipoprotein (oxLDL)/β glycoprotein I (β-GPI) complexes, antibodies to 60 kDa heat shock protein (anti-Hsp60), soluble urokinase plasminogen activator receptor (suPAR), and B-type natriuretic peptide (BNP) fragment in sera of RA and AS patients undergoing anti-TNF treatment.

View Article and Find Full Text PDF

In sepsis, platelets may become activated via toll-like receptors (TLRs), causing microvascular thrombosis. Megakaryocytes (MKs) also express these receptors; thus, severe infection may modulate thrombopoiesis. To explore the relevance of altered miRNAs in platelet activation upon sepsis, we first investigated sepsis-induced miRNA expression in platelets of septic patients.

View Article and Find Full Text PDF

Increased cardiovascular (CV) morbidity and mortality have been found in rheumatoid arthritis (RA). Tumour necrosis factor α (TNF-α) inhibitors may improve vascular function. In the first part of this study, we determined microcirculation during postoocclusive reactive hyperemia (PORH) representing endothelial function.

View Article and Find Full Text PDF

Accelerated atherosclerosis, increased cardiovascular morbidity and mortality have been associated with rheumatoid arthritis (RA) and ankylosing spondylitis (AS). Vascular function, clinical and laboratory markers and the effects of anti-TNF therapy were assessed in arthritides. Fifty-three 53 patients including 36 RA patients treated with either etanercept (ETN) or certolizumab pegol and 17 AS patients treated with ETN were included in a 12-month follow-up study.

View Article and Find Full Text PDF

We assessed cognitive function of female rheumatoid arthritis (RA) patients and analyze the determinants, with special focus on cerebrovascular morphology. Sixty methotrexate (MTX-) or biologic-treated RA patients and 39 healthy controls were included in a cross-sectional study. Smoking habits, alcohol intake and time spent in education were recorded.

View Article and Find Full Text PDF

Objectives: Impaired vascular pathophysiology and increased cardiovascular (CV) mortality are associated with rheumatoid arthritis (RA). To date, no genomic analysis of RA- and RA treatment-related vascular pathophysiology has been published. In this pilot study, we performed gene expression profiling in association with vascular pathophysiology in RA patients.

View Article and Find Full Text PDF

Several inflammatory, proteolytic, angiogenic and bone-associated factors play a role in the development of autoimmune, accelerated atherosclerosis in rheumatic diseases. Some of these may serve as biomarkers of vascular pathology and may be useful in the follow-up of vascular damage and outcome. Multi-biomarker profiles rather than a single markers would likely be optimal in this respect.

View Article and Find Full Text PDF